Moderna's stock performance is being closely watched, with some reports indicating it is outperforming other vaccine stocks and the broader health care sector. However, there are also reports of the stock experiencing significant drops, suggesting uncertainty about its overall performance. The company's vaccine development, including its influenza vaccine, is also being discussed in relation to its stock prospects.